title: Phospholipase C mediates (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-, but not lysergic acid diethylamide (LSD)-elicited head bobs in rabbit medial prefrontal cortex.
abstract: The phenethylamine and indoleamine classes of hallucinogens demonstrate distinct pharmacological properties, although they share a serotonin(2A) (5-HT(2A)) receptor mechanism of action (MOA). The 5-HT(2A) receptor signals through phosphatidylinositol (PI) hydrolysis, which is initiated upon activation of phospholipase C (PLC). The role of PI hydrolysis in the effects of hallucinogens remains unclear. In order to better understand the role of PI hydrolysis in the MOA of hallucinogens, the PLC inhibitor, 1-[6-((17β-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl]-1H-pyrrole-2,5-dione (U73122), was used to study the effects of two hallucinogens, the phenethylamine, (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), and the indoleamine, lysergic acid diethylamide (LSD). PI hydrolysis was quantified through release of [3H]inositol-4-phosphate from living rabbit frontocortical tissue prisms. Head bobs were counted after hallucinogens were infused into the medial prefrontal cortex (mPFC) of rabbits. Both DOI and LSD stimulated PI hydrolysis in frontocortical tissue through activation of PLC. DOI-stimulated PI hydrolysis was blocked by 5-HT(2A/2C) receptor antagonist, ketanserin, whereas the LSD signal was blocked by 5-HT(2B/2C) receptor antagonist, SB206553. When infused into the mPFC, both DOI- and LSD-elicited head bobs. Pretreatment with U73122 blocked DOI-, but not LSD-elicited head bobs. The two hallucinogens investigated were distinct in their activation of the PI hydrolysis signaling pathway. The serotonergic receptors involved with DOI and LSD signals in frontocortical tissue were different. Furthermore, PLC activation in mPFC was necessary for DOI-elicited head bobs, whereas LSD-elicited head bobs were independent of this pathway. These novel findings urge closer investigation into the intracellular mechanism of action of these unique compounds.
authors.affiliation: Drexel University College of Medicine, Department of Pharmacology & Physiology, 245 N. 15th Street, Philadelphia, PA 19102, United States. eman227@gmail.com
authors.forename: Emmanuelle A D
authors.initials: EA
authors.lastname: Schindler
authors.forename: John A
authors.initials: JA
authors.lastname: Harvey
authors.forename: Vincent J
authors.initials: VJ
authors.lastname: Aloyo
mesh_terms: D000662:Amphetamines / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects* / Q000502:physiology*; D002540:Cerebral Cortex; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004963:Estrenes / Q000494:pharmacology; D006213:Hallucinogens / Q000008:administration & dosage / Q000494:pharmacology*; D019416:Head Movements / Q000187:drug effects* / Q000502:physiology*; D006868:Hydrolysis; D008238:Lysergic Acid Diethylamide / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008845:Microinjections; D010716:Phosphatidylinositols / Q000378:metabolism; D017397:Prefrontal Cortex / Q000502:physiology*; D011760:Pyrrolidinones / Q000494:pharmacology; D011817:Rabbits; D044402:Receptor, Serotonin, 5-HT2A / Q000187:drug effects; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors / Q000502:physiology*
chemical_list: D000662:Amphetamines; D004791:Enzyme Inhibitors; D004963:Estrenes; D006213:Hallucinogens; D010716:Phosphatidylinositols; D011760:Pyrrolidinones; D044402:Receptor, Serotonin, 5-HT2A; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; C060229:1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione; D008238:Lysergic Acid Diethylamide; D010738:Type C Phospholipases; C015952:4-iodo-2,5-dimethoxyphenylisopropylamine